Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers.

Our mission is to revolutionize drug development as medicines today are often toxic and unselective, working only for a small percentage of patients and leaving behind a trail of negative side effects. We aspire to change this paradigm and are developing highly selective, targeted medicines, that address known mutations in patients that have been pre-identified to respond effectively to our therapies.

Our goal is to utilize our capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.

The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” At Biomea Fusion, we develop medicines to improve the life of the individual.